Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. (Nasdaq: AMPH) develops, manufactures, and commercializes technically challenging generic and proprietary injectable, inhalation, and intranasal medicines, as well as active pharmaceutical ingredients (APIs). Its products serve hospitals, long-term care facilities, clinics, doctors’… From the company’s description.
Over the twelve months to Sep 30, 2026, Amphastar Pharmaceuticals, Inc. reported revenue of $745.79M, up 3.1% from a year earlier, and net income of $98.96M. Its operating margin was 18.7%, and operations generated $175.33M in cash. In fiscal 2025, it reported revenue of $719.89M, down 1.7% from fiscal 2024, and net income of $98.09M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Amphastar Pharmaceuticals, Inc. does
In the company’s own words
Amphastar Pharmaceuticals, Inc. (Nasdaq: AMPH) develops, manufactures, and commercializes technically challenging generic and proprietary injectable, inhalation, and intranasal medicines, as well as active pharmaceutical ingredients (APIs). Its products serve hospitals, long-term care facilities, clinics, doctors’ offices, and retail pharmacies, with distribution through wholesalers, specialty distributors, and group purchasing organizations. The company markets more than 25 prescription products and an over-the-counter medicine, including BAQSIMI nasal glucagon, Primatene MIST, glucagon, epinephrine, lidocaine, enoxaparin, and naloxone; it also sells insulin APIs to third parties. Amphastar operates as an integrated business spanning research and development, API production, manufacturing, and commercialization, rather than reporting separate business segments. Its pipeline includes generic drugs, interchangeable insulin biosimilars, and proprietary candidates. In 2025, net revenue was $719.9 million. The acquisition of BAQSIMI in 2023 expanded its intranasal portfolio and international presence; the product is available in the United States and 26 international markets. Its website is www.amphastar.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- RANCHO CUCAMONGA, CA
- Fiscal year end
- December
- CIK
- 1297184
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Amphastar Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Amphastar Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Amphastar Pharmaceuticals, Inc.’s bonds, as funds hold them
Funds report holding 1 issues of Amphastar Pharmaceuticals, Inc.’s debt, $30.27M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 2.00%, maturing 2029 to 2029.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Amphastar Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Amphastar Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Amphastar Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”